Past China Practices Come to Light As GSK Settles FCPA Probe
Executive Summary
The US SEC has accepted a $20m payment from GSK to settle charges that it violated US legislation on foreign corrupt practices, in a decision that also throws further light on the UK-based firm's past sales inducement activities in China.